{
    "symbol": "TKNO",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-10 19:43:18",
    "content": " While we have revised our 2022 revenue outlook, I want to reiterate our belief that the fundamental growth opportunity for Teknova remains unchanged, and we are confident in our ability to help our customers accelerate the introduction of novel therapies through our unique ability to manufacture custom-made reagents in volume less than 1,000 liters and with short turnaround times. Total revenue was $11.7 million for the second quarter of 2022, a 41% increase from $8.3 million in the second quarter of 2021. Lab Essential's revenue was $8.4 million in the second quarter, a 30% increase from $6.5 million in the second quarter of 2021 and an 18% increase on a trailing 12-month basis. Our Clinical Solutions revenue was $2.9 million in the second quarter, an 85% increase from $1.6 million in the second quarter of 2021 and a 91% increase on a trailing 12-month basis. Net loss for the second quarter of 2022 was $6.2 million or $0.22 per diluted share, compared to a net loss of $2.3 million or $0.52 per diluted share for the second quarter of 2021. Adjusted EBITDA, a non-GAAP measure, was negative $4.9 million for the second quarter of 2022, compared to negative $1.5 million for the second quarter of 2021. Free cash flow, a non-GAAP measure, which we define as cash provided by or used in operating activities, less purchases of property, plant and equipment, in the second quarter was negative $16.8 million compared to negative $8.2 million in the second quarter of 2021."
}